NASDAQ:PTX

Pernix Therapeutics (PTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.03
$0.21
52-Week Range
N/A
Volume
16,105 shs
Average Volume
3.04 million shs
Market Capitalization
$419,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PTX stock logo

About Pernix Therapeutics Stock (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

PTX Stock News Headlines

Bicycle Therapeutics PLC ADR BCYC
Prescient Therapeutics Ltd
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Pernix Therapeutics Holdings Inc (PTX)
See More Headlines
Receive PTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PTX
CUSIP
71426V10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-77,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$146.07 million
Book Value
($14.77) per share

Miscellaneous

Free Float
N/A
Market Cap
$419,000.00
Optionable
Optionable
Beta
1.20
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. John Anthony Sedor (Age 74)
    Chairman & CEO
  • Mr. Kenneth R. Pina Esq. (Age 60)
    Sr. VP, Chief Legal & Compliance Officer and Corp. Sec.
  • Mr. Glenn Whaley (Age 51)
    VP of Fin., Principal Financial & Accounting Officer
  • Mr. Anthony M. Orrico
    VP of Technical & Supply Operations
  • Mr. George P. Jones
    VP of Sales & Marketing

PTX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Pernix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI), Argos Therapeutics (ARGSQ), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN) and (FPP) (FPP).

This page (NASDAQ:PTX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners